Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2023-09-10 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券之发行保荐书 (2023年半年报更新稿)
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding the issuance of convertible bonds by 益丰大药房连锁股份有限公司 (Yifeng Pharmacy Chain Co., Ltd.). It contains detailed information about the bond issuance, the sponsor's commitments, legal and regulatory compliance, financial data, shareholder information, and the underwriting process. The document is a formal sponsorship letter related to a capital raising activity involving convertible bonds. It is not an earnings release, annual report, or audit report, nor is it a simple announcement or certification. It is a detailed document related to capital/financing update activities, specifically the issuance of convertible bonds to unspecified investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2023-09-10 Chinese
关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券的审核中心意见落实函的回复报告(2023年半年报更新稿)
Regulatory Filings Classification · 95% confidence The document is a detailed reply report from a company and its sponsor (underwriter) addressing regulatory inquiries related to the issuance of convertible bonds. It includes detailed explanations about administrative penalties, compliance, and legal opinions regarding the company's operations and regulatory matters. The document references a specific regulatory review and response to a Shanghai Stock Exchange inquiry letter dated May 15, 2023, concerning the issuance of convertible bonds. It contains no financial statements or earnings data but focuses on regulatory compliance and legal clarifications. The document length is 7,566 characters, which is substantial and contains detailed content, not just an announcement or a brief note. Given the nature of the content—response to regulatory inquiries and legal compliance related to a financing activity—the most appropriate classification is a Regulatory Filing (RNS), as it does not fit the definitions of Annual Report, Audit Report, Capital/Financing Update, or other categories. It is not a report publication announcement since it contains substantive content, not just a notice of report availability.
2023-09-10 Chinese
天健会计师事务所(特殊普通合伙) 关于益丰大药房连锁股份有限公司公开发行可转债申请文件反馈意见中有关财务事项的说明 (2023年半年报更新稿)
Audit Report / Information Classification · 95% confidence The document is a detailed financial and operational explanation related to the company's acquisitions and goodwill accounting. It includes extensive financial data, audit references, and detailed descriptions of acquisition processes, valuation methods, and financial conditions of acquired entities. The document references regulatory feedback from the China Securities Regulatory Commission and includes audit reports and financial analysis. The length is substantial (15,000 characters), and the content is comprehensive, indicating it is not a brief announcement or a certification. The document is focused on financial matters related to acquisitions and goodwill, which are typically part of audit or financial review reports rather than full annual or quarterly reports. It does not appear to be a full annual report (10-K) or interim report (IR) but rather a detailed audit-related explanation and response to regulatory feedback on financial matters. Therefore, the most appropriate classification is Audit Report / Information (AR). H1 2022
2023-09-10 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券的补充法律意见书 (六)
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's issuance of convertible bonds to unspecified investors. It references regulatory bodies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange, and discusses compliance with securities laws and regulations. The document includes extensive legal analysis, verification of shareholder and management participation in the bond issuance, administrative penalties, and other legal matters related to the bond issuance process. It is not a financial report, earnings release, or a simple announcement. It is a legal opinion and verification document related to a capital raising activity (issuance of convertible bonds). Therefore, the document best fits the category of Capital/Financing Update (CAP).
2023-09-10 Chinese
益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券募集说明书 (上会稿) (2023年半年报更新稿)
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to "Offering Prospectus" or "Issuance Prospectus" for convertible bonds issued by Yifeng Pharmacy Chain Co., Ltd. It contains detailed information about the bond issuance, including the nature of the convertible bonds, credit ratings, risk factors, company background, financial information, management commitments, and legal statements. The document is comprehensive and lengthy (15,000 characters), indicating it is the actual prospectus rather than a brief announcement. This type of document is related to capital raising activities and financing updates. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-09-10 Chinese
中信证券股份有限公司关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券之上市保荐书 (2023年半年报更新稿)
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to a "Listing Sponsorship Letter" or "Sponsorship Document" related to the issuance of convertible corporate bonds by Yifeng Pharmacy Chain Co., Ltd. It is issued by CITIC Securities as the sponsor and underwriter. The content includes detailed information about the issuer, the bond issuance terms, risk factors, financial data, and regulatory compliance. This type of document is typically associated with capital market transactions, specifically the issuance of securities and related sponsorship and underwriting activities. It is not an annual report, earnings release, or management discussion. It is a detailed capital/financing update document related to a convertible bond issuance to unspecified investors. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the full report, not just an announcement or certification.
2023-09-10 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.